Oramed Pharmaceuticals Inc. plans a secondary listing in Tel Aviv “in the next few weeks” to take advantage of an increasing number of Israeli investors seeking new opportunities amid new measures to invigorate the stock market, CEO Nadav Kidron told Bloomberg.
Oral insulin to be a game changer: Oramed CEO Nadav Kidron tells CNBC On Squawk Box Asia, Kidron talks about the company's latest offering
Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about the conclusion of the Phase IIb study, and about what's next for Oramed: Oramed hopes to start Phase 3 oral insulin trial next year
Injectable insulin has been around since 1923, but oral insulin has proven elusive to date. Oramed Pharmaceuticals' successful Phase IIB trial for oral insulin has shown that it can be done. http://seekingalpha.com/article/3987206-oramed-now-first-show-evidence-insulin-can-taken-orally
Creating a safe, effective, tolerable oral insulin has become the holy grail of diabetes drug development, and Israel-based Oramed is one of the frontrunners in this race... http://www.biopharmadive.com/news/orameds-oral-insulin-shines-in-mid-stage-trials/419657/
Be Forum: Dancing With Dragons, How a Small Israeli Company Struck a Historic Deal with a Chinese Giant
Josh Hexter, Oramed's COO, spoke with Be Forum and about the company's recent China deal. www.beforum.org/the-bulletin/dancing-with-dragons
Josh Hexter, Oramed's COO, spoke with BioTuesdays.com about Oramed's progress and future advances. "Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and [...]